ConSynance Therapeutics’ CSTI-500 Receives the US FDA’s Rare Pediatric Disease Designation to Treat Prader-Willi Syndrome
Shots:
- The US FDA has granted rare pediatric disease designation (RPDD) to the company’s CSTI-500 for treating Prader-Willi Syndrome (PWS) among children & adolescents. On FDA's approval for PWS, ConSynance will receive a transferable Priority Review Voucher
- CSTI-500 has shown brain target engagement among healthy subjects through PET; these findings and additional PK outcomes confirm its effectiveness in PWS & other neuropsychiatric indications. Its P-II trial is anticipated during 2025
- CSTI-500 (oral) an FIC Triple Monoamine Reuptake Inhibitor (TRI), is developed to elevate serotonin, dopamine & norepinephrine levels in neurons; low levels of these neurotransmitters cause PWS
Ref: Globenewswire | Image: ConSynance Therapeutics
Related News:- Tonix Pharmaceuticals’ IND Application for TNX-2900 Receives the US FDA’s Approval for the Treatment of Prader-Willi Syndrome (PWS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
